instead, we prioritized peer-reviewed research that directly addressed psychiatric or mechanistic outcomes of GLP-1 receptor agonists
Strategic Implications/Executive Takeaways Focus on Multi-Condition Solutions: As GLP-1 receptor agonists gain traction in treating both type 2 diabetes and obesity, companies should emphasize these dual benefits to capture a broader patient base
In addition to blunted monoaminergic neurotransmission, it was also shown that deficiency in neurotrophic factor effects, disturbances in neurogenesis and synaptogenesis, chronic neuroinflammatory processes, and dysregulation of the hypothalamicpituitaryadrenal (HPA) axis can largely contribute to the manifestation of depressive symptoms in patients [3,4,5]
If No Worries can genuinely help with these problems Langers might be on to something.
Labels look impressive, ingredient lists sound familiar, and yet the results don't always match expectations